Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Biogen Inc BIIB

Healthcare Biotechnology
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BIIB)

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

GlobeNewswire 3 days ago

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

GlobeNewswire 8 days ago

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference

GlobeNewswire October 30, 2024

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases

GlobeNewswire October 29, 2024

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

GlobeNewswire October 29, 2024

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

GlobeNewswire October 28, 2024

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

GlobeNewswire October 26, 2024

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

GlobeNewswire October 24, 2024

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

GlobeNewswire October 22, 2024
View More News ››

Opinion & Analysis (NDAQ:BIIB)

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

Streetwise Reports November 7, 2019

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings

Streetwise Reports October 23, 2019

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

Streetwise Reports March 7, 2019

Potential Alzheimer's therapies focus on early intervention

Streetwise Reports December 1, 2017

Big biotech's value is bolstered by focus on Alzheimer's disease

The Life Sciences Report November 1, 2017

Possible 'best-in-class' alzheimer's drug candidate offers 'disruptive' potential

The Life Sciences Report September 21, 2017
View More Opinion ››

Bullboard Posts (NDAQ:BIIB)

Biogen (NASDAQ:BIIB) &#8211; A Diversified Powerhouse Naviga

http://beyondspx.com/2024/07/31/biogen-nasdaqbiib-a-diversified-powerhouse-navigating-the-evolving-pharmaceutical-landscape/
MikeTester - August 2, 2024

Lignans Market Trends, Demand, Share and Reports 2021-2026

According to IMARC Group’s latest report, titled “Lignans Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast...
edwardebreen15 - August 9, 2022

RE:Biogen Sees Two Long-Time Directors Announce Retirement

A little fresh blood in management is good.
Joe455 - May 29, 2022

Biogen Sees Two Long-Time Directors Announce Retirement

Biogen Inc appears to be facing issues related to its executive team. The firm this morning indicated that two long time directors of...
AwareInvestor - January 31, 2022

Outrageous that this was ever approved.

They fail to mention the brain lesions, edema, and bleeding that this drug causes.  They fail to mention that the average AD...
TinToronto - June 12, 2021

$BIIB THE PATH AHEAD ISN’T EASY!

BIOGEN SCORES A BIG WIN FOR ADUHELM™, BUT THE PATH AHEAD ISN’T EASY!
AviseAnalytics - June 9, 2021
View more Bullboard ››

Coelacanth Energy Inc.

Coelacanth Energy Inc.

Coelacanth Energy Inc. is a Montney-focused oil and natural gas exploration and development company, with lands located in ...
View More »